<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334239</url>
  </required_header>
  <id_info>
    <org_study_id>01VSF17020</org_study_id>
    <nct_id>NCT04334239</nct_id>
  </id_info>
  <brief_title>Effectiveness of Care in Certified Cancer Centres in Germany</brief_title>
  <acronym>WiZen</acronym>
  <official_title>Wirksamkeit Der Versorgung in Onkologischen Zentren</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tumorzentrum Regensburg, Institut für Qualitätssicherung und Versorgungsforschung, Universität Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft Deutscher Tumorzenten e.V., ADT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wissenschaftliches Institut der AOK (WIdO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the effectiveness of care in certified cancer centres for eight cancer entities
      via a retrospective cohort study based on secondary data from statutory health insurance
      funds and population-based clinical cancer registries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer constitutes the second most frequent cause of death in Germany. To maintain a high
      quality of treatment, the national cancer plan aims at a unified certification of cancer
      centres.

      The project &quot;Wirksamkeit der Versorgung in onkologischen Zentren&quot; (WiZen) investigates
      effects of treatments in certified cancer centres across large populations and different
      cancer entities in comparison to hospitals that do not hold a certificate.

      WiZen is a retrospective comparative cohort study that analyzes incident cases of eight types
      of cancer diagnosed within 2009-2017 based on nationwide health insurance data provided by
      WIdO (the AOK research institute) and data from regional clinical cancer registries (CCR) for
      the period 2006-2017. These eight types of cancer are colorectal cancer, pancreatic cancer,
      breast cancer, gynecologic tumors, lung cancer, prostate cancer, head and neck tumors and
      neuro-oncological tumors.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>first hospitalization (starting from 01/01/2009 [WIdO] or 01/01/2006 [CCR]), up to 31/12/2017</time_frame>
    <description>Survival after first hospitalization due to cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1- and 5-year survival</measure>
    <time_frame>first hospitalization (starting from 01/01/2009 [WIdO] or 01/01/2006 [CCR]) with 1 or 5-year follow-up, respectively</time_frame>
    <description>1- and 5-year survival after first hospitalization due to cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>first hospitalization (starting from 01/01/2009 [WIdO] or 01/01/2006 [CCR]) with 30 days follow-up</time_frame>
    <description>30-day mortality after first hospitalization due to cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-, 3-, 4-year survival</measure>
    <time_frame>first hospitalization (starting from 01/01/2009 [WIdO] or 01/01/2006 [CCR]) with 2,3, or 4-year follow-up, respectively</time_frame>
    <description>2-, 3-, 4-year survival after first hospitalization due to cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>cancer diagnosis (starting from 01/01/2009 [WIdO] or 01/01/2006 [CCR]), up to 31/12/2017</time_frame>
    <description>Recurrence-free survival after cancer diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative recurrence rate</measure>
    <time_frame>cancer diagnosis (starting from 01/01/2009 [WIdO] or 01/01/2006 [CCR]), up to 31/12/2017</time_frame>
    <description>Cumulative recurrence rate after cancer diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications due to surgery</measure>
    <time_frame>date of initial cancer surgery with entity-specific follow-up</time_frame>
    <description>Complications due to cancer surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successive resection</measure>
    <time_frame>second resection within three months of initial cancer surgery</time_frame>
    <description>Second resection due to cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Entity-specific outcomes defined by clinical experts</measure>
    <time_frame>2009-2017 [CCR] or 2006-2017 [WIdO]</time_frame>
    <description>Fractions of entity-specific surgery techniques
For head-neck-tumours: aspiration pneumonia due to swallowing dysfunctions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of patients</measure>
    <time_frame>2009-2017</time_frame>
    <description>Fraction of patients in certified centres and in non-certified hospitals over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional differences</measure>
    <time_frame>2009-2017</time_frame>
    <description>Differences across outcomes in different counties or federal states</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in patient characteristics</measure>
    <time_frame>2009-2017 [CCR] or 2006-2017 [WIdO]</time_frame>
    <description>Differences in demographic characteristics, disease severity and risk factors across certified centres/non-certified hospitals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathways of treatment</measure>
    <time_frame>2009-2017</time_frame>
    <description>Patient's treatment pathways among general practitioners, specialists, and hospitals w.r.t. certification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity Levels in insurance data</measure>
    <time_frame>2009-2017</time_frame>
    <description>Deduction of cancer severity levels through linkage of health insurance and cancer registry data</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500000</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Cervix Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Bronchial Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Head and Neck Tumor</condition>
  <condition>CNS Tumor</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <description>Cancer patients who have undergone substantial parts of inpatient treatment in a certified cancer centre.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Cancer patients who have not undergone inpatient treatment in a certified cancer centre.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oncological certification</intervention_name>
    <description>Oncological certification encompasses a variety of criteria such as treatment according to the clinical guidelines, staffing, technical infrastructure, minimum caseloads, and multidisciplinary care.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        German residents with continuous insurance of one of the AOK funds 2006-2017 and patients
        recorded in one of the participating cancer registries Dresden, Erfurt, Regensburg and
        Berlin-Brandenburg 2006-2017
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first hospitalization due to diagnosis of colorectal cancer, pancreatic cancer, breast
             cancer, gynecologic tumors, lung cancer, prostate cancer, head and neck tumors, or
             neuro-oncological tumors 2009-2017 [WIdO]

          -  hospitalization due to primary diagnosis of colorectal cancer, pancreatic cancer,
             breast cancer, gynecologic tumors, lung cancer, prostate cancer, head and neck tumors,
             or neuro-oncological tumors 2006-2017 [CCR]

        Exclusion Criteria:

          -  prevalent diagnosis of colorectal cancer, pancreatic cancer, breast cancer,
             gynecologic tumors, lung cancer, prostate cancer, head and neck tumors, or
             neuro-oncological tumors 2006-2017

          -  exception: outpatient cancer diagnosis up to 12 months prior to first hospitalization
             is not regarded as prevalent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Technische Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Jochen Schmitt.</investigator_full_name>
    <investigator_title>Prof. Dr. med. Jochen Schmitt, MPH</investigator_title>
  </responsible_party>
  <keyword>quality of treatment</keyword>
  <keyword>institution of treatment</keyword>
  <keyword>certification</keyword>
  <keyword>cancer centres</keyword>
  <keyword>quality of care</keyword>
  <keyword>treatment outcome</keyword>
  <keyword>health services research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Bronchogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

